Outcomes and clinicopathologic characteristics associated with disseminated tumor cells in bone marrow after neoadjuvant chemotherapy in high-risk early stage breast cancer: the I-SPY SURMOUNT study

Magbanua, Mark Jesus M.; Veer, Laura van ‘t; Clark, Amy S.; Chien, Amy Jo; Boughey, Judy C.; Han, Hyo S.; Wallace, Anne M.; Beckwith, Heather; Liu, Minetta C.; Yau, Christina; Wileyto, E. Paul; Ordonez, Andrea D.; Solanki, Tulasi I.; Hsiao, Feng; Lee, Jen‐Chieh; Basu, Amrita; Swigart, Lamorna Brown; Perlmutter, Jane; Delson, Amy L.; Bayne, Lauren J.; Deluca, Shannon; Yee, Stephanie S.; Esserman, Laura J.; Park, John W.; Chodosh, Lewis A.; DeMichele, Angela

doi:10.1007/s10549-022-06803-0

Cited by 3 publications

(1 citation statement)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is apparent in studies of ctDNA in the context of neoadjuvant treatment for breast cancer. For instance, in the large I-SPY study reported that early clearance of ctDNA was associated with pathological complete response (pCR) in the breast only in patients with triple negative breast cancer (26). Cavallone et al (27) reported that early clearance of ctDNA had a relatively low predictive value of 50% for pCR.…”

Section: Discussionmentioning

confidence: 99%

Personalized circulating tumor DNA response to local radiotherapy in a patient with an early lobular breast cancer: A case report

Capella,

Fallah,

Basik

2024

Oncol Lett

View full text Add to dashboard Cite

The detection of circulating tumor DNA (ctDNA) in the plasma of cancer patients is emerging as a very sensitive and specific prognostic biomarker. Previous studies with ctDNA have focused on the ability of ctDNA detection to predict micrometastatic and eventual clinical metastatic relapse. There are few data on the role of ctDNA in monitoring response to local therapy. The present study reports the case of a patient with early-stage lobular breast cancer, with a detectable ctDNA test which resolved with local radiotherapy to the breast. This case suggests that ctDNA is sensitive enough to detect the response of minimal residual disease, localized in the breast, to radiation therapy, and thus may assist in providing indications for local breast cancer treatment.

show abstract

Section: Discussionmentioning

confidence: 99%